August 5 PDUFA Date Set for Moderna's Flu Vaccine; Q1 GAAP Loss Driven by Litigation Charge
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna announced an August 5 PDUFA date for its mRNA-1010 flu vaccine, a critical regulatory milestone. The company also reported a Q1 GAAP net loss, primarily attributed to a significant litigation charge, though an adjusted loss was smaller. This update follows earlier news today regarding the Q1 GAAP loss, but provides new, material details on its cause and the specific PDUFA timeline. The PDUFA date is a key catalyst, especially given the FDA's prior agreement to re-review the vaccine after an earlier rejection. Investors will be closely watching the FDA's decision on August 5, which could significantly impact the stock.
At the time of this announcement, MRNA was trading at $45.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.